Astria Therapeutics, Inc. (ATXS)

Market Cap	718.13M +50.2%
Revenue (ttm)	706,000
Net Income	-124.03M
EPS	-2.14
Shares Out	57.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,199,309
Open	12.48
Previous Close	n/a
Day's Range	12.45 - 12.59
52-Week Range	3.56 - 13.29
Beta	0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 10, 2026

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error